Bio waiver for lower strength (250mg) Mycophenolate mofetil tablet [Regulatives / Guidelines]

posted by jag009  – NJ, 2019-11-07 19:52  – Posting: # 20762
Views: 1,652

Hi,

» Please, I would like to know that, with the In vitro comparative dissolution study report can we waive off BE In vivo study with in vitro comparative dissolution study for the lower strength for Mycophenolate mofetil tablet 250mg or do we require separate BE study for the lower strength.

Are the strengths formulation proportional? FDA or EMA?

» And also I would like to know that whether similar approach can be taken for all the pro-drug where the metabolite of the drug is pharmacologically active.

FDA yes. Take a look at enalapril BE guidance.

J

Complete thread:

Activity
 Admin contact
20,778 posts in 4,351 threads, 1,444 registered users;
online 28 (0 registered, 28 guests [including 12 identified bots]).
Forum time: 10:19 CEST (Europe/Vienna)

All we know about the world teaches us that the effects of A and B
are always different—in some decimal place—for any A and B.
Thus asking “are the effects different?” is foolish.    John W. Tukey

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5